Compass Therapeutics (CMPX) Other Non-Current Liabilities (2019)
Compass Therapeutics recorded quarterly Other Non-Current Liabilities of $494000.0 in Q4 2019.
Compass Therapeutics' Other Non-Current Liabilities history runs 1 years deep, the most recent figure standing at $494000.0 for Q4 2019.
- In Q4 2019, Other Non-Current Liabilities changed N/A year-over-year to $494000.0; the TTM figure through Dec 2019 stood at $494000.0 (changed N/A YoY), while the FY2019 annual figure was $494000.0, changed N/A from the prior year.
- Other Non-Current Liabilities came in at $494000.0 for Q4 2019 at Compass Therapeutics.
- In the past five years, Other Non-Current Liabilities ranged from a high of $494000.0 in Q4 2019 to a low of $494000.0 in Q4 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 494,000.00 |